Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia

British Journal of Haematology

Volumn 119, Issue 3, 2002, Pages 769-772

  Hessling, Jörg ^a   Kröger, Nicolaus ^a   Werner, Mathias ^a   Zabelina, Tatjana ^a   Hansen, Arne ^a   Kordes, Uwe ^a   Ayuk, Francis Etang ^a   Renges, Helmut ^a   Panse, Jörg ^a   Erttmann, Rudolf ^a   Zander, Axel Rolf ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Allogeneic stem cell transplantation; Dose reduced conditioning; Graft versus host disease; Myelofibrosis with myeloid metaplasia; Non myeloablative transplantation

Indexed keywords

BUSULFAN; FLUDARABINE; THYMOCYTE ANTIBODY;

ADULT; AGE; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FIBROSIS; GRAFT VERSUS HOST REACTION; HUMAN; LEUKOCYTE COUNT; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION;

ADULT; BUSULFAN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIDARABINE;

EID: 18744371539     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03884.x     Document Type: Article

References (12)

1. Barosi, G. (1999) Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines. Journal of Clinical Oncology, 17, 2954-2970.
2. Byrne, J.L., Beshti, H., Clark, D., Ellis, I., Haynes, A.P., Das-Gupta, E. & Russell, N.H. (2000) Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: Evidence for a 'graft vs. myelofibrosis' effect. British Journal of Haematology, 108, 430-433.
3. Cervantes, F., Barosi, G., Demory, J.L., Reilly, J., Guarnone, R., Dupriez, B., Pereira, A. & Montserrat, E. (1998) Myelofibrosis with myeloid metaplasia in young individuals: Disease characteristics, prognostic factors and identification of risk groups. British Journal of Haematology, 102, 684-690.
4. Cervantes, F., Rovira, M., Urbano-Ispizua, A., Rozman, M., Carreras, E. & Montserrat, E. (2000) Complete remission of idiopathic myelofibrosis following donor lymphocyteinfusion after failure of allogeneic transplantation: Demonstration of a graft-versus-myelofibrosis effect. Bone Marrow Transplantation, 26, 697-699.
5. Devine, S.M., Hoffman, R., Verma, A., Shah, R., Bradlow, B.A., Stock, W., Maynard, V., Jessorp, E., Peace, D., Huml, M., Thomason, D., Chen, Y. & van Besien, K. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, 2255-2258.
6. Dupriez, B., Morel, P., Demory, J.L., Lai, J.L., Simon, M., Plantier, I. & Bauters, F. (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood, 88, 1013-1018.
7. Guardiola, P., Anderson, J.E., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., de Witte, T., Deeg, H.J. & Gluckman, E. (1999) Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood, 93, 2831-2838.
8. Kröger, N., Zabelina, T., Krüger, W., Renges, H., Stute, N., Dürken, M., Finkenstein, F., Erttmann, R., Kabisch, H., Schafhausen, P., Jaburg, N., Löliger, C. & Zander, A.R. (2001) Anti-Thymocyte-Globulin as part of the preparative regimen prevents acute and chronic Graft versus Host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors. Annals of Haematology, 80, 209-215.
9. McSweeney, P., Niederwieser, D., Shizuru, J.A., Sandmaier, B.M., Molina, A.J., Maloney, D.G., Chauncey, T.R., Gooley, T.A., Hegenbart, U., Nash, R.A., Radich, J., Wagner, J.L., Minor, S., Appelbaum, F.R., Bensinger, W.I., Bryant, E., Flowers, M.E., Georges, G.E., Grumet, F.C., Kiem, H.P., Torok-Storb, B., Yu, C., Blume, K.G. & Storb, R.F. (2001) Hematopoietic cell transplantation in older patients with hematological malignancies: replacing high-dose cytotoxic therapy with graft versus tumor effects. Blood, 97, 3390-3400.
10. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756-763.
11. Tefferi, A. (2000) Myelofibrosis with myeloid metaplasia. New England Journal of Medicine, 342, 1255-1265.
12. Zander, A.R., Zabelina, T., Kröger, N., Renges, H., Krüger, W., Löliger, C., Dürken, M., Stockschläder, M., de Wit, M., Wacker-Backhaus, G., Bielack, S., Jaburg, N., Rüssmann, B., Erttmann, R. & Kabisch, H. (1999) Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplantation, 23, 889-893.